Market revenue in 2024 | USD 35.2 million |
Market revenue in 2033 | USD 105.7 million |
Growth rate | 13% (CAGR from 2025 to 2033) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2021 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2033 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 67.9% in 2024. Horizon Databook has segmented the Brazil head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2021 to 2033.
In Latin America, Brazil has the largest population. Brazil has witnessed positive economic growth due to the region's recent financial and political stability. The pharmaceutical industry has shown greater improvements than other industries in the country, owing to increasing government investments to enhance healthcare infrastructure.
The increasing incidence of head & neck cancer and rising awareness about cancer diagnosis & treatments are s driving the market. According to an article published in the BMC Oral Health, in Brazil, it is estimated that there will be around 11,180 & 4,100 new cases of oral and oropharyngeal cancer annually in men & women, respectively, over the three-year period of 2020 to 2022.
Initiatives to promote early diagnosis and treatment of cancer are expected to increase the rate of treatment. In July 2022, genomics firm Geneseeq partnered with Hospital de Base in Brazil to establish an NGS-based precision oncology laboratory.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Brazil head and neck cancer therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
No related statistics found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account